Phase 3 study results for oral PCSK9 inhibition with enlicitide
{{output}}
Two large randomized, placebo-controlled phase 3 trials, CORALreef Lipids1 and CORALreef heFH,2 demonstrated that once-daily oral enlicitide lowered LDL cholesterol by approximately 56%-60% on top of background lipid-lowering therapy. Reductions were sustained... ...
